Search Filters:

The items contained in the list are being used to filter the search results. Click them to remove them from the search filter.
Displaying 21 - 40 of 874
PIPS Search Results
PIP Number Active Substance Conditions / Indications Invented Name Therapeutic area Decision Type Compliance Check Compliance outcome Date Published Sort ascending
MHRA-101902-PIP01-25
  • Bleximenib
  • Treatment of acute myeloid leukaemia
  • Oncology
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No
MHRA-101727-PIP01-24-M01 (update)
  • RAVULIZUMAB
  • Treatment of primary immunoglobulin A nephropathy
  • Ultomiris
  • Ultomiris
  • Ultomiris
  • Uro-Nephrology
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-100614-PIP01-22-M04 (update)
  • VONICOG ALFA
  • Treatment of von Willebrand Disease
  • veyvondi
  • Vonvendi
  • veyvondi
  • veyvondi
  • Vonvendi
  • veyvondi
  • Vonvendi
  • Haematology-Hemostaseology
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-102362-PIP01-26
  • Telisotuzumab adizutecan
  • Treatment of all conditions included in the category of malignant neoplasms.
  • Oncology
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No
MHRA-101362-PIP01-24-M02 (update)
  • ZANAMIVIR
  • Treatment of Influenza
  • Prevention of Influenza
  • Dectova
  • Dectova
  • Infectious diseases
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-102117-PIP01-25
  • Efimosfermin alfa
  • Treatment of metabolic dysfunction-associated steatohepatitis
  • Gastroenterology-Hepatology
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No
MHRA-100468-PIP01-22-M04 (update)
  • EPTINEZUMAB
  • Prevention of migraine headaches
  • Vyepti
  • VYEPTI 100 mg concentrate for solution for infusion
  • VYEPTI 300 mg concentrate for solution for infusion
  • Neurology
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-102116-PIP01-25
  • Delpacibart etedesiran
  • Treatment of myotonic disorders
  • Not available at present
  • Neurology
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No
MHRA-100348-PIP01-21-M02 (update)
  • botaretigene sparoparvovec
  • Treatment of retinitis pigmentosa
  • Ophthamology
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-102502-PIP01-26
  • Cemacabtagene ansegedleucel (cema-cel)
  • Treatment of non-Hodgkin B-cell lymphomas.
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-102207-PIP01-25-M01 (update)
  • Dazukibart
  • Treatment of idiopathic inflammatory myopathy
  • Other: Musculoskeletal and connective tissue disorders, Skin and subcutaneous tissue disorders
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-100232-PIP01-21-M01 (update)
  • ALECTINIB HYDROCHLORIDE
  • All conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue neoplasms)
  • Alecensa
  • Oncology
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-100325-PIP01-21-M03 (update)
  • NALDEMEDINE
  • Treatment of opioid-induced constipation
  • Rizmoic
  • Rizmoic
  • SYMPROIC
  • SYMPROIC
  • SYMPROIC
  • SYMPROIC
  • SYMPROIC
  • Gastroenterology-Hepatology
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-101980-PIP01-25
  • Group B Streptococcus 6-valent polysaccharide conjugate vaccine (GBS6)
  • Prevention of Group B Streptococcus invasive disease via maternal immunisation.
  • Not available at present
  • Vaccines
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No
MHRA-101827-PIP01-25
  • Apazunersen
  • Treatment of Angelman syndrome
  • Not available at present
  • Neurology
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No
MHRA-102346-PIP01-26
  • Sonrotoclax
  • Treatment of mantle cell lymphoma (MCL)
  • Treatment of chronic lymphocytic leukaemia (CLL) / small lymphocytic lymphoma (SLL)
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-102405-PIP01-26
  • BIIB122 (proposed INN: liradasertib)
  • Treatment of Parkinson's disease
  • Neurology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-100982-PIP01-23-M02 (update)
  • pegunigalsidase alfa
  • Treatment of Fabry disease
  • Elfabrio
  • Elfabrio
  • Elfabrio
  • Elfabrio
  • Elfabrio
  • Elfabrio
  • Elfabrio
  • Elfabrio
  • Elfabrio
  • Elfabrio
  • Elfabrio
  • Elfabrio
  • Elfabrio
  • Elfabrio
  • Endocrinology-Gynaecology-Fertility-metabolism
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-102550-PIP01-26
  • Humanised IgG1 (LALA) monoclonal antibody against folate receptor alfa, conjugated with exatecan
  • Treatment of peritoneal cancer.
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-102549-PIP01-26
  • Humanised IgG1 (LALA) monoclonal antibody against folate receptor alfa, conjugated with exatecan
  • Treatment of ovarian cancer.
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No